NCT04877613View on ClinicalTrials.gov

GFRα4 CAR T Cells in MTC Patients

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 19, 2021

Primary Completion Date

June 1, 2039

Study Completion Date

June 1, 2039

Conditions
Metastatic Medullary Thyroid CancerRecurrent Thyroid Gland Medullary Carcinoma
Interventions
DRUG

single dose of CART-GFRa4 cells

Intravenous infusion of lentiviral transduced autologous T cells that have been engineered to express an extracellular single chain antibody (scFv) with specificity towards GFRa4 with fludarabine and cyclophosphamide.

DRUG

Fludarabine

Lymphodepletion

DRUG

Cyclophosphamide

Lymphodepletion

Trial Locations (1)

19104

University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

University of Pennsylvania

OTHER